Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Gains from Investment Securities (2018 - 2026)

Champions Oncology (CSBR) has 7 years of Gains from Investment Securities data on record, last reported at $97000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $97000.0; the TTM value through Oct 2025 reached $227000.0, down 2.99%, while the annual FY2025 figure was $150000.0, 11.24% down from the prior year.
  • Gains from Investment Securities reached $97000.0 in Q4 2025 per CSBR's latest filing, up from -$20000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.9 million in Q1 2021 and bottomed at -$66000.0 in Q4 2021.
  • Average Gains from Investment Securities over 4 years is $652100.0, with a median of $83500.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 193500.0% in 2021, down 29.74% in 2021.
  • A 4-year view of Gains from Investment Securities shows it stood at -$66000.0 in 2021, then increased by 1.52% to -$65000.0 in 2023, then surged by 98.46% to -$1000.0 in 2024, then soared by 9800.0% to $97000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $97000.0 in Q4 2025, -$20000.0 in Q3 2025, and $150000.0 in Q2 2025.